Generic Name and Formulations:
Triazolam 0.125mg, 0.25mg+; tabs; +scored.
Indications for HALCION:
Short-term (7–10 days) treatment of insomnia.
Use lowest effective dose. ≥18yrs: 0.125–0.25mg at bedtime; max 0.5mg. Elderly and/or debilitated: initially 0.125mg; max 0.25mg. Max 1 month/℞.
<18yrs: not established.
Concomitant ketoconazole, itraconazole, nefazodone, HIV protease inhibitors (eg, ritonavir, indinavir, nelfinavir, saquinavir, lopinavir), other potent CYP3A inhibitors. Pregnancy (Cat.X).
Risks from concomitant use with opioids; see Interactions. Suicidal tendencies. Depression. Pulmonary, renal, or hepatic disease. Sleep apnea. Discontinue if excitement or daytime anxiety occurs. Drug or alcohol abuse. Overdosage may occur at 2mg. Reevaluate if used ≥2–3 weeks. Avoid abrupt cessation. Monitor periodic CBCs, urinalysis, blood chemistry. Nursing mothers: not recommended.
See Contraindications; other azole antifungals: not recommended. Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants (eg, other benzodiazepines, TCAs, psychotropics, anticonvulsants, antihistamines); consider dose reductions. Potentiated by ranitidine, grapefruit juice, isoniazid, oral contraceptives. Reduce triazolam dose with cimetidine, erythromycin, clarithromycin, other macrolides. Caution with fluvoxamine, diltiazem, verapamil, sertraline, paroxetine, ergotamine, cyclosporine, amiodarone, nicardipine, nifedipine, others metabolized by CYP3A.
Drowsiness, headache, dizziness, nervousness, light-headedness, ataxia, nausea, vomiting; worsening of insomnia, sleep-driving and other complex behaviors, paradoxical excitement, anxiety, abnormal behavior, amnesia, anaphylaxis, angioedema.
Endocrinology Advisor Articles
- Testosterone Use Remains High Among Men With Coronary Artery Disease
- Primary Characteristics of PCOS Predictive of Obstetric Complications
- Comparing Osteoporosis Screening, Treatment Strategies in Postmenopausal Women
- Maternal Thyroid Function in Pregnancy Linked to Childhood Risk for Disease
- Cerebral Small Vessel Disease More Common in Individuals With T1D vs General Population
- ADA's 2019 Standards of Medical Care in Diabetes Focus on Patient-Centered Care
- Sleep Habits Affect Insulin Sensitivity in Adolescents With Overweight, Obesity
- Levothyroxine Associated With Increased Mortality in Patients With Heart Failure
- Head-to-Head Comparison of Professional vs Personal CGM Systems in T1D
- Dual vs Triple Therapy for Metformin Treatment Intensification in Type 2 Diabetes
- Risk for Congenital Heart Defects in Offspring of Mothers With Obesity
- Is the MiniMed 670G System Safe for Children With Type 1 Diabetes?
- Gender-Affirming Hormonal Treatment and Long-Term Bone Safety
- Obesity Linked to Lower Gray Matter Brain Volume
- No Evidence for Health Benefits of Nonsugar Sweeteners